标题：甲酯 4-（7-羟基-4,4,8-三甲基-3-氧杂二环[3.3.1]壬烷-2-基）苯甲酸酯的合成与评价及其与米替福新的协同抗利什曼原虫作用
Synthesis and Evaluation of Methyl 4-(7-Hydroxy-4,4,8-Trimethyl-3-Oxabicyclo[3.3.1]Nonan-2-yl)Benzoate as an Antileishmanial Agent and Its Synergistic Effect with Miltefosine.
机构信息
Department of Biosciences and Bioengineering, Indian Institute of Technology Guwahati, Assam, India.
Department of Chemistry, Indian Institute of Technology Guwahati, Assam, India.
出版信息
Antimicrob Agents Chemother. 2018 Jan 25;62(2). doi: 10.1128/AAC.01810-17. Print 2018 Feb.
Abstract
In our interest in oxabicyclic compounds as potent antileishmanial agents, the present work deals with the chemical synthesis of a new oxabicyclic derivative, methyl 4-(7-hydroxy-4,4,8-trimethyl-3-oxabicyclo[3.3.1]nonan-2-yl)benzoate (PS-207). This oxabicyclic derivative showed a good antileishmanial effect on the parasite, on both the promastigote and the amastigote. The mode of parasitic death from PS-207 seemed to be apoptosis-like. Interestingly, the combination of PS-207 with a low dose of miltefosine showed a synergistic effect against the parasite.
摘要
在我们对作为强效抗利什曼原虫药物的氧杂双环化合物的研究兴趣中，本工作涉及一种新的氧杂双环衍生物——甲酯 4-(7-羟基-4,4,8-三甲基-3-氧杂双环[3.3.1]壬烷-2-基)苯甲酸酯（PS-207）的化学合成。该氧杂双环衍生物对寄生虫表现出良好的抗利什曼原虫作用，无论是对前鞭毛体还是无鞭毛体。PS-207 引起寄生虫死亡的方式似乎类似于细胞凋亡。有趣的是，PS-207 与低剂量米替福新联合使用对寄生虫表现出协同作用。
相似文献
1
Synthesis and Evaluation of Methyl 4-(7-Hydroxy-4,4,8-Trimethyl-3-Oxabicyclo[3.3.1]Nonan-2-yl)Benzoate as an Antileishmanial Agent and Its Synergistic Effect with Miltefosine.
Antimicrob Agents Chemother. 2018 Jan 25;62(2). doi: 10.1128/AAC.01810-17. Print 2018 Feb.
2
Novel Agents against Miltefosine-Unresponsive Leishmania donovani.
Antimicrob Agents Chemother. 2015 Dec;59(12):7826-9. doi: 10.1128/AAC.00928-15. Epub 2015 Sep 21.
3
Inactivation of the miltefosine transporter, LdMT, causes miltefosine resistance that is conferred to the amastigote stage of Leishmania donovani and persists in vivo.
Int J Antimicrob Agents. 2007 Sep;30(3):229-35. doi: 10.1016/j.ijantimicag.2007.05.007. Epub 2007 Jul 12.
4
In vitro activity of new N-benzyl-1H-benzimidazol-2-amine derivatives against cutaneous, mucocutaneous and visceral Leishmania species.
Exp Parasitol. 2018 Jan;184:82-89. doi: 10.1016/j.exppara.2017.11.009. Epub 2017 Dec 1.
5
Lipase Precursor-Like Protein Promotes Miltefosine Tolerance in Leishmania donovani by Enhancing Parasite Infectivity and Eliciting Anti-inflammatory Responses in Host Macrophages.
Antimicrob Agents Chemother. 2018 Nov 26;62(12). doi: 10.1128/AAC.00666-18. Print 2018 Dec.
6
CpG oligodeoxynucleotide augments the antileishmanial activity of miltefosine against experimental visceral leishmaniasis.
J Antimicrob Chemother. 2010 Jul;65(7):1448-54. doi: 10.1093/jac/dkq164. Epub 2010 May 22.
7
15d-Prostaglandin J2 induced reactive oxygen species-mediated apoptosis during experimental visceral leishmaniasis.
J Mol Med (Berl). 2016 Jun;94(6):695-710. doi: 10.1007/s00109-016-1384-5. Epub 2016 Feb 1.
8
Nanotized Curcumin and Miltefosine, a Potential Combination for Treatment of Experimental Visceral Leishmaniasis.
Antimicrob Agents Chemother. 2017 Feb 23;61(3). doi: 10.1128/AAC.01169-16. Print 2017 Mar.
9
Possible mechanism of miltefosine-mediated death of Leishmania donovani.
Antimicrob Agents Chemother. 2004 Aug;48(8):3010-5. doi: 10.1128/AAC.48.8.3010-3015.2004.
10
Synthesis and biological evaluation of ferrocenylquinoline as a potential antileishmanial agent.
ChemMedChem. 2015 Mar;10(3):546-54. doi: 10.1002/cmdc.201402537. Epub 2015 Jan 23.
本文引用的文献
1
Methionine aminopeptidase 2 is a key regulator of apoptotic like cell death in Leishmania donovani.
Sci Rep. 2017 Mar 7;7(1):95. doi: 10.1038/s41598-017-00186-9.
2
Novel Agents against Miltefosine-Unresponsive Leishmania donovani.
Antimicrob Agents Chemother. 2015 Dec;59(12):7826-9. doi: 10.1128/AAC.00928-15. Epub 2015 Sep 21.
3
Combinations of ascaridole, carvacrol, and caryophyllene oxide against Leishmania.
Acta Trop. 2015 May;145:31-8. doi: 10.1016/j.actatropica.2015.02.002. Epub 2015 Feb 17.
4
Molecular mechanism underlying antileishmanial effect of oxabicyclo[3.3.1]nonanones: inhibition of key redox enzymes of the pathogen.
Eur J Pharm Biopharm. 2013 Nov;85(3 Pt A):569-77. doi: 10.1016/j.ejpb.2013.08.014. Epub 2013 Aug 31.
5
In vitro interaction between paromomycin sulphate and four drugs with leishmanicidal activity against three New World Leishmania species.
J Antimicrob Chemother. 2014 Jan;69(1):150-4. doi: 10.1093/jac/dkt318. Epub 2013 Aug 22.
6
Leishmaniasis worldwide and global estimates of its incidence.
PLoS One. 2012;7(5):e35671. doi: 10.1371/journal.pone.0035671. Epub 2012 May 31.
7
Leishmaniasis: current status of available drugs and new potential drug targets.
Asian Pac J Trop Med. 2012 Jun;5(6):485-97. doi: 10.1016/S1995-7645(12)60084-4.
8
Efficacy of miltefosine in the treatment of visceral leishmaniasis in India after a decade of use.
Clin Infect Dis. 2012 Aug;55(4):543-50. doi: 10.1093/cid/cis474. Epub 2012 May 9.
9
Cost-effectiveness analysis of combination therapies for visceral leishmaniasis in the Indian subcontinent.
PLoS Negl Trop Dis. 2010 Sep 7;4(9):e818. doi: 10.1371/journal.pntd.0000818.
10
Flow cytometric screening for anti-leishmanials in a human macrophage cell line.
Exp Parasitol. 2010 Dec;126(4):617-20. doi: 10.1016/j.exppara.2010.06.007. Epub 2010 Jun 9.
Zotero 插件